527 related articles for article (PubMed ID: 28737834)
1. Vitamin K antagonists versus low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism.
Andras A; Sala Tenna A; Stewart M
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD002001. PubMed ID: 28737834
[TBL] [Abstract][Full Text] [Related]
2. Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair.
Forster R; Stewart M
Cochrane Database Syst Rev; 2016 Mar; 3(3):CD004179. PubMed ID: 27027384
[TBL] [Abstract][Full Text] [Related]
3. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.
Rutjes AW; Porreca E; Candeloro M; Valeriani E; Di Nisio M
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD008500. PubMed ID: 33337539
[TBL] [Abstract][Full Text] [Related]
4. Vitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism.
van der Heijden JF; Hutten BA; Büller HR; Prins MH
Cochrane Database Syst Rev; 2002; (1):CD002001. PubMed ID: 11869618
[TBL] [Abstract][Full Text] [Related]
5. Vitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism.
van Der Heijden JF ; Hutten BA; Büller HR; Prins MH
Cochrane Database Syst Rev; 2000; (4):CD002001. PubMed ID: 11034739
[TBL] [Abstract][Full Text] [Related]
6. Anticoagulation for the long term treatment of venous thromboembolism in patients with cancer.
Akl EA; Barba M; Rohilla S; Terrenato I; Sperati F; Muti P; Schünemann HJ
Cochrane Database Syst Rev; 2008 Apr; (2):CD006650. PubMed ID: 18425959
[TBL] [Abstract][Full Text] [Related]
7. Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of pulmonary embolism.
Li M; Li J; Wang X; Hui X; Wang Q; Xie S; Yan P; Tian J; Li J; Xie P; Yang K; Yao L
Cochrane Database Syst Rev; 2023 Apr; 4(4):CD010957. PubMed ID: 37057837
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of low- molecular- weight- heparin versus vitamin K antagonists for long term treatment of cancer-associated venous thromboembolism in adults: a systematic review of randomized controlled trials.
Louzada ML; Majeed H; Wells PS
Thromb Res; 2009 Apr; 123(6):837-44. PubMed ID: 18977517
[TBL] [Abstract][Full Text] [Related]
9. Long-term use of different doses of low-molecular-weight heparin versus vitamin K antagonists in the treatment of venous thromboembolism.
Romera-Villegas A; Cairols-Castellote MA; Vila-Coll R; Martí-Mestre X; Colomé E; Iguaz I
Ann Vasc Surg; 2010 Jul; 24(5):628-39. PubMed ID: 19932949
[TBL] [Abstract][Full Text] [Related]
10. Direct thrombin inhibitors versus vitamin K antagonists or low molecular weight heparins for prevention of venous thromboembolism following total hip or knee replacement.
Salazar CA; Malaga G; Malasquez G
Cochrane Database Syst Rev; 2010 Apr; 2010(4):CD005981. PubMed ID: 20393944
[TBL] [Abstract][Full Text] [Related]
11. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer.
Akl EA; Vasireddi SR; Gunukula S; Barba M; Sperati F; Terrenato I; Muti P; Schünemann H
Cochrane Database Syst Rev; 2011 Feb; (2):CD006649. PubMed ID: 21328285
[TBL] [Abstract][Full Text] [Related]
12. Treatment of venous thromboembolism in patients with cancer: A network meta-analysis comparing efficacy and safety of anticoagulants.
Posch F; Königsbrügge O; Zielinski C; Pabinger I; Ay C
Thromb Res; 2015 Sep; 136(3):582-9. PubMed ID: 26210891
[TBL] [Abstract][Full Text] [Related]
13. Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of deep vein thrombosis.
Wang X; Ma Y; Hui X; Li M; Li J; Tian J; Wang Q; Yan P; Li J; Xie P; Yang K; Yao L
Cochrane Database Syst Rev; 2023 Apr; 4(4):CD010956. PubMed ID: 37058421
[TBL] [Abstract][Full Text] [Related]
14. Low-molecular-weight heparin for the long-term treatment of symptomatic venous thromboembolism: meta-analysis of the randomized comparisons with oral anticoagulants.
Iorio A; Guercini F; Pini M
J Thromb Haemost; 2003 Sep; 1(9):1906-13. PubMed ID: 12941030
[TBL] [Abstract][Full Text] [Related]
15. Anticoagulation for patients with cancer and central venous catheters.
Akl EA; Vasireddi SR; Gunukula S; Yosuico VE; Barba M; Sperati F; Cook D; Schünemann H
Cochrane Database Syst Rev; 2011 Feb; (2):CD006468. PubMed ID: 21328283
[TBL] [Abstract][Full Text] [Related]
16. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism.
Erkens PM; Prins MH
Cochrane Database Syst Rev; 2010 Sep; (9):CD001100. PubMed ID: 20824828
[TBL] [Abstract][Full Text] [Related]
17. Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery.
Rasmussen MS; Jørgensen LN; Wille-Jørgensen P
Cochrane Database Syst Rev; 2009 Jan; (1):CD004318. PubMed ID: 19160234
[TBL] [Abstract][Full Text] [Related]
18. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer.
Akl EA; Rohilla S; Barba M; Sperati F; Terrenato I; Muti P; Schünemann HJ
Cochrane Database Syst Rev; 2008 Jan; (1):CD006649. PubMed ID: 18254108
[TBL] [Abstract][Full Text] [Related]
19. Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism.
Vardi M; Zittan E; Bitterman H
Cochrane Database Syst Rev; 2009 Oct; (4):CD006771. PubMed ID: 19821386
[TBL] [Abstract][Full Text] [Related]
20. Primary prophylaxis for venous thromboembolism in patients undergoing cardiac or thoracic surgery.
Di Nisio M; Peinemann F; Porreca E; Rutjes AW
Cochrane Database Syst Rev; 2015 Jun; 2015(6):CD009658. PubMed ID: 26091835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
